← Leaderboards
Ji Chen Bihl
Wright State University
$1,990,035
Attributed
$1,990,035
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $490.9K · FY2017–22$500K$375K$250K$125K$0
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$1,990,035 · 2
By mechanism
R01$1,631,875 · 1
R21$358,160 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Membrane”
- Ted Ross · University Of Georgia$71,962,304
- Gary Fanger · Rise Therapeutics, Llc$21,703,466
- Thomas Denny · Duke University$19,381,749
- Leonard Freedman · Leidos Biomedical Research, Inc.$15,756,756
- Jurgen Bernd Bulitta · State University Of New York At Buffalo$10,599,402
- Mary E Hamby · Cognition Therapeutics, Inc.$9,832,688
Research focus
MembraneDesignProteinsMicrornasCellsBloodMediatingProductionVesicleReactive Oxygen SpeciesCerebrovascular SystemAcuteApoptosisBrainCerebrovascular CirculationClinically RelevantAngioplastyCell CommunicationCause Of DeathAutophagocytosisCell HypoxiaAxonCell MotilityCell Survival
Grant awards (7)
Exosomes from miR-primed endothelial progenitor cells for treating ischemic stroke$323,750
R01 · FY2022 · NS · contact PI
Exosomes from miR-primed endothelial progenitor cells for treating ischemic stroke$323,750
R01 · FY2021 · NS · contact PI
Exosomes from miR-primed endothelial progenitor cells for treating ischemic stroke$328,125
R01 · FY2020 · NS · contact PI
Exosomes from miR-primed endothelial progenitor cells for treating ischemic stroke$328,125
R01 · FY2019 · NS · contact PI
Exosomes from miR-primed endothelial progenitor cells for treating ischemic stroke$328,125
R01 · FY2018 · NS · contact PI
Microvesicles as a Novel Transmitter for UVB-Induced Bioactive Products$162,800
R21 · FY2018 · AR · contact PI
Microvesicles as a Novel Transmitter for UVB-Induced Bioactive Products$195,360
R21 · FY2017 · AR · contact PI